Orchestra BioMed (OBIO) versus The Competition Head to Head Comparison

Orchestra BioMed (NASDAQ:OBIO) is one of 228 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Orchestra BioMed to similar companies based on the strength of its institutional ownership, dividends, risk, profitability, analyst recommendations, earnings and valuation.

Profitability

This table compares Orchestra BioMed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-1,779.71%	-58.32%	-41.47%
Orchestra BioMed Competitors	-600.78%	-148.39%	-27.16%

Valuation and Earnings

This table compares Orchestra BioMed and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	-$49.12 million	-2.93
Orchestra BioMed Competitors	$977.87 million	-$5.74 million	-8.91

Orchestra BioMed’s rivals have higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 47.5% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.6% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Orchestra BioMed has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s rivals have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Orchestra BioMed and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
Orchestra BioMed Competitors	1585	4103	7996	194	2.49

Orchestra BioMed presently has a consensus target price of $17.00, suggesting a potential upside of 287.24%. As a group, “Surgical & medical instruments” companies have a potential upside of 32.80%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, equities analysts clearly believe Orchestra BioMed is more favorable than its rivals.

Summary

Orchestra BioMed rivals beat Orchestra BioMed on 7 of the 13 factors compared.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.